1. Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly(I:C) in a murine colorectal tumor model. Link
    Park JS, Kim HS, Park HM, Kim CH, Kim TG.
    Vaccine. 2011 Nov 3;29(47):8642-8.
  2. Enhanced Induction of T Cell Immunity Using Dendritic Cells Pulsed with HIV Tat and HCMV-pp65 Fusion Protein In Vitro. Link
    Park JS, Park SY, Cho HI, Sohn HJ, Kim TG.
    Immune Netw. 2011 Jun;11(3):182-9.
  3. Induction of antitumor immunity using dendritic cells electroporated with Polo-like kinase 1 (Plk1) mRNA in murine tumor models. Link
    Park JS, Sohn HJ, Park GS, Chung YJ, Kim TG.
    Cancer Sci. 2011 Aug;102(8):1448-54
  4. Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model. Link
    Kim HS, Park HM, Park JS, Sohn HJ, Kim SG, Kim HJ, Oh ST, Kim TG.
    Vaccine. 2010 Nov 16;28(49):7787-96
  5. Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model. Link
    Lee JM, Yoon SH, Kim HS, Kim SY, Sohn HJ, Oh ST, Oh IH, Kim TG.
    Cancer Gene Ther.
  6. Fusion of the HCMV pp65 antigen with both ubiquitin and ornithine decarboxylase additionally enhances antigen presentation to CD8+ T cells in human dendritic cells.
    Park MJ, Kim EK, Han JY, Cho HW, Sohn HJ, Kim SY, Kim TG.
    Hum Gene Ther. 2010 Mar 10. [Epub ahead of print]
  7. Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model.
    Kim HS, Kim CH, Park MY, Park JS, Park HM, Sohn HJ, Kim HJ, Kim SG, Oh ST, Kim TG.
    Immunol Lett. 2010 Mar 6.
  8. Topoisomerase II alpha as a universal tumor antigen: antitumor immunity in murine tumor models and H-2K(b)-restricted T cell epitope.
    Park JS, Kim HS, Park MY, Kim CH, Chung YJ, Hong YK, Kim TG.
    Cancer Immunol Immunother. 2010 May;59(5):747-57.
  9. Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR).
    Yoon SH, Lee JM, Woo SJ, Park MJ, Park JS, Kim HS, Park MY, Sohn HJ, Kim TG.
    J Clin Immunol. 2009 Nov;29(6):806-14. Epub 2009 Jun 11.
  10. Selective addition of CXCR3(+) CCR4(-) CD4(+) Th1 cells enhances generation of cytotoxic T cells by dendritic cells in vitro.
    Yoon SH, Yun SO, Park JY, Won HY, Kim EK, Sohn HJ, Cho HI, Kim TG.
    Exp Mol Med. 2009 Mar 31;41(3):161-70.
  11. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model.
    Yoon SH, Lee JM, Cho HI, Kim EK, Kim HS, Park MY, Kim TG.
    Cancer Gene Ther. 2009 Jun;16(6):489-97. Epub 2008 Dec 19.
  12. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination.
    Kim SG, Park MY, Kim CH, Sohn HJ, Kim HS, Park JS, Kim HJ, Oh ST, Kim TG.
    Vaccine. 2008 Nov 25;26(50):6433-40. Epub 2008 Sep 21.
  13. Efficient antitumor immunity in a murine colorectal cancer model induced by CEA RNA-electroporated B cells.
    Park MY, Kim HS, Woo SJ, Kim CH, Park JS, Sohn HJ, Kim HJ, Oh ST, Kim TG.
    Eur J Immunol. 2008 Aug;38(8):2106-17
  14. Efficient generation of survivin-specific cytotoxic T lymphocytes from healthy persons in vitro: quantitative and qualitative effects of CD4+ T cells.
    Kim EK, Cho HI, Yoon SH, Park MJ, Sohn HJ, Kim HJ, Oh ST, Kim TG.
    Vaccine. 2008 Jul 29;26(32):3987-97. Epub 2008 Jun 6
  15. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity.
    Woo SJ, Kim CH, Park MY, Kim HS, Sohn HJ, Park JS, Kim HJ, Oh ST, Kim TG.
    Cancer Sci. 2008 May;99(5):1034-9. Epub 2008 Feb 24.
  16. A membrane-bound form of IL-4 enhances proliferation and antigen presentation of CD40-activated human B cells.
    Park JY, Yoon SH, Kim EK, Yun SO, Park MY, Sohn HJ, Kim TG.
    Immunol Lett. 2008 Feb 15;116(1):33-40. Epub 2007 Dec 3.
  17. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein.
    Cho HI, Kim EK, Park SY, Lee SK, Hong YK, Kim TG.
    Cancer Lett. 2007 Dec 18;258(2):189-98. Epub 2007 Oct 10.
  18. The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity.
    Park MY, Kim CH, Sohn HJ, Oh ST, Kim SG, Kim TG.
    Vaccine. 2007 Oct 16;25(42):7322-30. Epub 2007 Sep 6
  19. Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma.
    Kim CH, Woo SJ, Park JS, Kim HS, Park MY, Park SD, Hong YK, Kim TG.
    Immunology. 2007 Dec;122(4):615-22. Epub 2007 Jul 20
  20. Direct vaccination with pseudotype baculovirus expressing murine telomerase induces anti-tumor immunity comparable with RNA-electroporated dendritic cells in a murine glioma model.
    Kim CH, Yoon JS, Sohn HJ, Kim CK, Paik SY, Hong YK, Kim TG